Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORT NYSEAMERICAN:CATX NYSE:INSP NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$25.36-28.4%$36.50$19.16▼$48.25$1.72B1.41340,683 shs5.14 million shsCATXPerspective Therapeutics$3.76+4.4%$4.56$1.96▼$6.16$410.46M1.751.58 million shs794,735 shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.31B0.831.18 million shs971,765 shsNVCRNovoCure$17.89+6.3%$12.41$9.82▼$20.06$1.95B0.91.76 million shs2.37 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+1.89%-1.14%+0.57%-10.41%+24.85%CATXPerspective Therapeutics-5.76%-7.69%-17.62%-23.57%+53.19%INSPInspire Medical Systems-0.81%-18.75%-16.25%-30.86%-71.01%NVCRNovoCure+2.00%+10.65%+62.61%+65.98%+1.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$25.36-28.4%$36.50$19.16▼$48.25$1.72B1.41340,683 shs5.14 million shsCATXPerspective Therapeutics$3.76+4.4%$4.56$1.96▼$6.16$410.46M1.751.58 million shs794,735 shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.31B0.831.18 million shs971,765 shsNVCRNovoCure$17.89+6.3%$12.41$9.82▼$20.06$1.95B0.91.76 million shs2.37 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+1.89%-1.14%+0.57%-10.41%+24.85%CATXPerspective Therapeutics-5.76%-7.69%-17.62%-23.57%+53.19%INSPInspire Medical Systems-0.81%-18.75%-16.25%-30.86%-71.01%NVCRNovoCure+2.00%+10.65%+62.61%+65.98%+1.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 2.88Moderate Buy$47.8388.59% UpsideCATXPerspective Therapeutics 3.11Buy$12.63235.77% UpsideINSPInspire Medical Systems 2.15Hold$85.0091.95% UpsideNVCRNovoCure 2.38Hold$27.2952.52% UpsideCurrent Analyst Ratings BreakdownLatest CATX, NVCR, AORT, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026AORTArtivion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$53.00 ➝ $48.005/8/2026AORTArtivion Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $44.005/7/2026INSPInspire Medical Systems OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform5/6/2026INSPInspire Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/5/2026INSPInspire Medical Systems Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$56.00 ➝ $45.005/5/2026INSPInspire Medical Systems EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.005/5/2026INSPInspire Medical Systems Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$85.00 ➝ $55.005/5/2026CATXPerspective Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2026INSPInspire Medical Systems JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$67.00 ➝ $54.005/5/2026INSPInspire Medical Systems Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/5/2026INSPInspire Medical Systems Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$64.00 ➝ $50.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$441.33M2.79$0.79 per share32.15$9.46 per share2.68CATXPerspective Therapeutics$880K487.18N/AN/A$2.79 per share1.35INSPInspire Medical Systems$911.98M1.40$2.78 per share15.91$27.50 per share1.61NVCRNovoCure$655.35M3.16N/AN/A$2.86 per share6.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion$9.77M$0.24105.6926.42N/A2.55%7.21%3.65%N/ACATXPerspective Therapeutics-$103.12MN/AN/AN/AN/A-11,665.27%-41.79%-34.76%5/11/2026 (Estimated)INSPInspire Medical Systems$145.42M$4.499.8625.304.7814.33%10.35%8.81%N/ANVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)Latest CATX, NVCR, AORT, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CATXPerspective Therapeutics-$0.29N/AN/AN/A$0.16 millionN/A5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million3/16/2026Q4 2025CATXPerspective TherapeuticsN/A-$0.51N/A-$0.51N/A$0.04 million2/26/2026Q4 2025NVCRNovoCure-$0.41-$0.22+$0.19-$0.22$174.40 million$174.35 million2/12/2026Q4 2025AORTArtivion$0.14$0.17+$0.03$0.05$116.42 million$118.30 million2/11/2026Q4 2025INSPInspire Medical Systems$0.69$1.65+$0.96$4.66$264.02 million$269.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion0.493.532.62CATXPerspective Therapeutics0.015.175.17INSPInspire Medical SystemsN/A6.344.56NVCRNovoCure0.712.902.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%CATXPerspective Therapeutics54.66%INSPInspire Medical Systems94.91%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipAORTArtivion6.30%CATXPerspective Therapeutics3.72%INSPInspire Medical Systems2.20%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,80048.50 million45.44 millionOptionableCATXPerspective Therapeutics70114.02 million109.78 millionOptionableINSPInspire Medical Systems1,33328.81 million28.18 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionableCATX, NVCR, AORT, and INSP HeadlinesRecent News About These CompaniesHC Wainwright Estimates NovoCure's Q2 Earnings (NASDAQ:NVCR)May 5 at 8:32 AM | marketbeat.comNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00 at Wells Fargo & CompanyMay 4, 2026 | marketbeat.comStocks with rising relative price strength: NovocureMay 4, 2026 | msn.comInternational Markets and NovoCure (NVCR): A Deep Dive for InvestorsMay 4, 2026 | zacks.comNovoCure (NASDAQ:NVCR) Shares Up 6.8% - Here's WhyMay 3, 2026 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 2, 2026 | finance.yahoo.comNovoCure (NASDAQ:NVCR) Trading 6.8% Higher - Should You Buy?May 1, 2026 | marketbeat.comNovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer YetMay 1, 2026 | seekingalpha.comNovoCure: Q1 Earnings SnapshotMay 1, 2026 | chron.comNovocure jumps after raising FY26 sales outlook, Q1 revenue beatMay 1, 2026 | seekingalpha.comTwo medical stocks skyrocket after demolishing views — and one is about to break outMay 1, 2026 | msn.comNovoCure (NVCR) Q1 2026 Earnings TranscriptMay 1, 2026 | finance.yahoo.comWhy NovoCure Limited’s (NVCR) Stock Is Up 19.53%May 1, 2026 | aaii.comANovoCure (NASDAQ:NVCR) Announces Earnings ResultsApril 30, 2026 | marketbeat.comNovoCure Limited (NVCR) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy?April 30, 2026 | marketbeat.comNovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesApril 30, 2026 | zacks.comNovoCure Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comNovoCure Limited 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by AnalystsApril 25, 2026 | marketbeat.comNovoCure (NVCR) to Release Quarterly Earnings on ThursdayApril 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, NVCR, AORT, and INSP Company DescriptionsArtivion NYSE:AORT$25.36 -10.06 (-28.39%) Closing price 03:58 PM EasternExtended Trading$25.33 -0.03 (-0.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Perspective Therapeutics NYSEAMERICAN:CATX$3.76 +0.16 (+4.44%) Closing price 04:10 PM EasternExtended Trading$3.74 -0.02 (-0.66%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Inspire Medical Systems NYSE:INSP$44.28 -1.29 (-2.83%) Closing price 03:58 PM EasternExtended Trading$44.26 -0.02 (-0.05%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.NovoCure NASDAQ:NVCR$17.89 +1.06 (+6.30%) Closing price 04:00 PM EasternExtended Trading$17.63 -0.26 (-1.45%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
